Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 02 05 2024
accepted: 04 07 2024
medline: 24 7 2024
pubmed: 24 7 2024
entrez: 23 7 2024
Statut: epublish

Résumé

Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the disease. Thus, identifying the features that will be associated with a confirmed diagnosis over time is key. To assess the frequency and the predisposing factors for a change of an initial diagnosis in an inception axSpA cohort. DESIR is an ongoing national multicentre inception axSpA cohort with currently 12.5 years of follow-up. At the entry visit and confirmed at each visit, the diagnosis of axSpA was based on the opinion of the treating rheumatologist. Follow-up was interrupted in case of a change in this initial diagnosis. Multiple imputation was used to estimate the probability of a change in the initial diagnosis of axSpA for each patient lost to follow-up. Factors predisposing to an unchanged diagnosis of axSpA were then assessed using a multivariate logistic regression model on the imputed data sets. Of the 708 patients included, over 10 years of follow-up, 45 (6.4%) were excluded due to a diagnosis change and 300 (42.4%) patients were lost to follow-up. Based on the imputation of these 300 patients, a change in their initial axSpA diagnosis was estimated in 42 (14.0%). Factors predisposing to an unchanged initial axSpA diagnosis during follow-up were (ORs (95% CIs)): radiographic sacroiliitis: 17.0 (4.1 to 71.0); psoriasis: 5.3 (2.0 to 14.3); CRP≥6 mg/L: 2.7 (1.3 to 5.3); good NSAID response: 2.5 (1.5 to 4.2); HLA B27+: 2.0 (1.3 to 3.3); anterior chest wall pain: 2.0 (1.2 to 3.3) and female sex: 1.9 (1.2 to 3.0). These data suggest that a change in diagnosis in recent onset axSpA exists, but is not frequent, and is less likely to occur in the presence of objective features at baseline.

Sections du résumé

BACKGROUND BACKGROUND
Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the disease. Thus, identifying the features that will be associated with a confirmed diagnosis over time is key.
OBJECTIVES OBJECTIVE
To assess the frequency and the predisposing factors for a change of an initial diagnosis in an inception axSpA cohort.
METHODS METHODS
DESIR is an ongoing national multicentre inception axSpA cohort with currently 12.5 years of follow-up. At the entry visit and confirmed at each visit, the diagnosis of axSpA was based on the opinion of the treating rheumatologist. Follow-up was interrupted in case of a change in this initial diagnosis. Multiple imputation was used to estimate the probability of a change in the initial diagnosis of axSpA for each patient lost to follow-up. Factors predisposing to an unchanged diagnosis of axSpA were then assessed using a multivariate logistic regression model on the imputed data sets.
RESULTS RESULTS
Of the 708 patients included, over 10 years of follow-up, 45 (6.4%) were excluded due to a diagnosis change and 300 (42.4%) patients were lost to follow-up. Based on the imputation of these 300 patients, a change in their initial axSpA diagnosis was estimated in 42 (14.0%). Factors predisposing to an unchanged initial axSpA diagnosis during follow-up were (ORs (95% CIs)): radiographic sacroiliitis: 17.0 (4.1 to 71.0); psoriasis: 5.3 (2.0 to 14.3); CRP≥6 mg/L: 2.7 (1.3 to 5.3); good NSAID response: 2.5 (1.5 to 4.2); HLA B27+: 2.0 (1.3 to 3.3); anterior chest wall pain: 2.0 (1.2 to 3.3) and female sex: 1.9 (1.2 to 3.0).
CONCLUSION CONCLUSIONS
These data suggest that a change in diagnosis in recent onset axSpA exists, but is not frequent, and is less likely to occur in the presence of objective features at baseline.

Identifiants

pubmed: 39043614
pii: rmdopen-2024-004484
doi: 10.1136/rmdopen-2024-004484
pii:
doi:

Substances chimiques

HLA-B27 Antigen 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Anna Molto (A)

Department of Rheumatology, Assistance Publique - Hôpitaux de Paris, Paris, France anna.molto@aphp.fr.
INSERM, Paris, France.

Chris Serrand (C)

Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nimes, France.

Sandrine Alonso (S)

Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ Montpellier, Nimes, France.

Francis Berenbaum (F)

Faculty of Medicine Pierre & Marie Curie Paris VI, Hopital Saint-Antoine, Paris, France.
Sorbonne Université, Paris, France.

Pascal Claudepierre (P)

Rheumatology, Hôpital Henri Mondor, Créteil, France.
EA EpidermE, Université Paris Est Créteil, Créteil, France.

Bernard Combe (B)

Rheumatology, CHU Montpellier, Montpellier, France.

Laure Gossec (L)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.
APHP, Rheumatology department, Hopital Universitaire Pitie Salpetriere, Paris, France.

Adeline Ruyssen-Witrand (A)

Department of Rheumatology, Paul Sabatier University Toulouse III, Toulouse, France.

Alain Saraux (A)

Rheumatology, CHU Brest, Brest, France.

Daniel Wendling (D)

Rheumatology, CHU J Minjoz, Besancon, France.

Thierry Lequerre (T)

Rheumatology Department, Rouen University Hospital, Inserm Unit 905 & Institute for Biomedical Research, University of Rouen, Rouen, France.

Maxime Dougados (M)

Hopital Cochin, Rheumatology, Université Paris Descartes Faculté de Médecine, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH